212 related articles for article (PubMed ID: 32006898)
1. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
3. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
Wu W; Lin Y; Xiang L; Dong W; Hua X; Ling Y; Li H; Yan F; Xie X; Gu W
Ann Hematol; 2016 Jun; 95(7):1051-7. PubMed ID: 27116384
[TBL] [Abstract][Full Text] [Related]
4. Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics.
Javorniczky NR; Grishina O; Hund I; Pantic M; Pfeifer D; Schmoor C; Thomas J; Duyster J; Becker H; Lübbert M
Clin Epigenetics; 2023 Nov; 15(1):185. PubMed ID: 38012682
[TBL] [Abstract][Full Text] [Related]
5. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
Grishina O; Schmoor C; Döhner K; Hackanson B; Lubrich B; May AM; Cieslik C; Müller MJ; Lübbert M
BMC Cancer; 2015 May; 15():430. PubMed ID: 26008690
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen.
Lai B; Mu Q; Zhang Y; Chen Y; Yan X; Ouyang G
Hematology; 2021 Dec; 26(1):751-757. PubMed ID: 34555298
[TBL] [Abstract][Full Text] [Related]
7. [Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
Meng YS; Ma XX; Meng XQ; Wei R; Liu W; Ai GW; Zhang YX
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3406-10. PubMed ID: 18476539
[TBL] [Abstract][Full Text] [Related]
8. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
[TBL] [Abstract][Full Text] [Related]
9. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
[No Abstract] [Full Text] [Related]
10. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
[TBL] [Abstract][Full Text] [Related]
11. [All-Trans Retinoic Acid and Decitabine Synergistically Induce Anti-Leukemia Effect on U937 Cell Line and Newly Diagnosed Elder AML Patients].
Dong WM; Cao Y; Xiang LL; Lin Y; Liu Y; Cen JN; Xie XB; Gu WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):964-971. PubMed ID: 30111392
[TBL] [Abstract][Full Text] [Related]
12. All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase.
Wang W; Jiang Z; Wang L; Wang A; Liu J; Chen C; Yu K; Zou F; Wang W; Liu J; Liu Q
Cancer Lett; 2020 Mar; 473():130-138. PubMed ID: 31904486
[TBL] [Abstract][Full Text] [Related]
13. The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation.
Meier R; Greve G; Zimmer D; Bresser H; Berberich B; Langova R; Stomper J; Rubarth A; Feuerbach L; Lipka DB; Hey J; Grüning B; Brors B; Duyster J; Plass C; Becker H; Lübbert M
Blood Cancer J; 2022 Aug; 12(8):122. PubMed ID: 35995769
[TBL] [Abstract][Full Text] [Related]
14. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
Blum W; Schwind S; Tarighat SS; Geyer S; Eisfeld AK; Whitman S; Walker A; Klisovic R; Byrd JC; Santhanam R; Wang H; Curfman JP; Devine SM; Jacob S; Garr C; Kefauver C; Perrotti D; Chan KK; Bloomfield CD; Caligiuri MA; Grever MR; Garzon R; Marcucci G
Blood; 2012 Jun; 119(25):6025-31. PubMed ID: 22566605
[TBL] [Abstract][Full Text] [Related]
17. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
Lübbert M; Grishina O; Schmoor C; Schlenk RF; Jost E; Crysandt M; Heuser M; Thol F; Salih HR; Schittenhelm MM; Germing U; Kuendgen A; Götze KS; Lindemann HW; Müller-Tidow C; Heil G; Scholl S; Bug G; Schwaenen C; Giagounidis A; Neubauer A; Krauter J; Brugger W; De Wit M; Wäsch R; Becker H; May AM; Duyster J; Döhner K; Ganser A; Hackanson B; Döhner H;
J Clin Oncol; 2020 Jan; 38(3):257-270. PubMed ID: 31794324
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat.
Blagitko-Dorfs N; Jiang Y; Duque-Afonso J; Hiller J; Yalcin A; Greve G; Abdelkarim M; Hackanson B; Lübbert M
PLoS One; 2013; 8(10):e75258. PubMed ID: 24116031
[TBL] [Abstract][Full Text] [Related]
19. Acquired persistently complete remission by decitabine-based treatment for acute myeloid leukemia with the
Wang F; Chen Y; Jiang N; Gong S; Cao T; Yuan J; Liu J; Xie L; Wu Y; Jia Y
Leuk Lymphoma; 2019 Dec; 60(13):3304-3307. PubMed ID: 31256701
[No Abstract] [Full Text] [Related]
20. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
